Investigator's Choice of Chemotherapy
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Genentech, Inc., Akeso, Hoffmann-La Roche, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Conditions
Advanced Unresectable or Metastatic Solid MalignancyBreast Cancer MetastaticCervical CancerCervical Cancer MetastaticClassical Hodgkin LymphomaEarly Breast CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Phase 2
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
CompletedNCT04632992
Start: 2021-01-13End: 2024-02-27Updated: 2025-01-08
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
RecruitingNCT05420779
Start: 2022-06-30End: 2026-06-30Target: 125Updated: 2024-05-08
Phase 3
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT04342936
Start: 2020-07-17End: 2023-12-01Target: 56Updated: 2021-02-08
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
RecruitingNCT05244642
Start: 2022-02-15End: 2026-03-30Target: 60Updated: 2022-02-17
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
CompletedNCT05415215
Start: 2022-07-05End: 2025-11-07Updated: 2026-02-10
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
RecruitingNCT05954442
Start: 2023-09-13End: 2026-08-31Target: 203Updated: 2024-01-16
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
RecruitingNCT07152405
Start: 2025-09-24End: 2027-06-30Target: 490Updated: 2025-11-17
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RecruitingNCT07214779
Start: 2025-12-09End: 2029-05-14Target: 466Updated: 2026-03-23
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Not yet recruitingNCT07230626
Start: 2025-11-20End: 2028-07-01Target: 412Updated: 2025-11-17
A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Not yet recruitingNCT07392060
Start: 2026-02-28End: 2030-06-30Target: 440Updated: 2026-02-06